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Abstract Human placental alkaline phosphatase (PALP) is
synthesized in the placenta during pregnancy and is also
expressed in many cancer patients; however, its physiological
role is unknown. Here we show that in human fetus fibroblasts as
well as normal and H-ras-transformed mouse embryo fibroblasts
PALP stimulates DNA synthesis and cell proliferation in
synergism with insulin, zinc and calcium. The mitogenic effects
of PALP are associated with the activation of c-Raf-1, p42/p44
mitogen-activated protein kinases, p70 S6 kinase, Akt/PKB
kinase and phosphatidylinositol 3P-kinase. The results suggest
that in vivo PALP may promote fetus development as well as the
growth of cancer cells which express oncogenic Ras.
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1. Introduction
Placental alkaline phosphatase (PALP) is a member of the
alkaline phosphatase (ALP) group of enzymes which hydro-
lyze phosphate containing compounds at alkaline pH [1],
although at neutral pH they also hydrolyze phosphatidic
acid and some other substrates [2,3]. The mature PALP is a
dimer of two identical glycosylated subunits [4]. The ALP
family also includes the tissue non-speci¢c (liver/bone/kidney)
ALP (TNSALP), intestinal ALP (IALP) and a PALP-like
enzyme, products of separate genes [5^8].
The primary source of human PALP is placenta, which
synthesizes this enzyme during the second and third trimester
of pregnancy. By term, PALP becomes a major ALP in the
circulation [9]. In pregnant women, decreased serum level of
PALP may be associated with intrauterine growth retardation
[10,11], premature rupture of membranes [12], premature la-
bor [12], or Down’s syndrome pregnancies [13], although these
correlations have not always been found [14]. All these obser-
vations suggest that PALP may play some role in the develop-
ment of the fetus.
Interestingly, PALP is also expressed in certain cancer pa-
tients [15^21], but its possible contribution to tumorigenesis
has not been established. Since the growth of fetus and tu-
mors show many common features, it is possible that in-
creased expression of PALP alters the growth of both fetal
and cancer tissues. To examine this possibility, we initiated a
study to determine the e¡ects of PALP on the growth of
untransformed and H-ras-transformed mouse NIH 3T3 ¢bro-
blasts as well as human fetus ¢broblasts. We have found that
in these cell lines, highly puri¢ed PALP can stimulate DNA
synthesis and cell proliferation via activation of various
known growth regulatory enzymes.
2. Materials and methods
2.1. Materials
Human PALP, TNSALP from bovine kidney, IALP from bovine
intestinal mucosa (unit of ALP activity always de¢ned as given in
Sigma catalog) and (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) were bought from Sigma. Insulin was purchased
from Boehringer Mannheim. [Methyl-3H]thymidine (500 mCi/mmol)
and [Q-32P]ATP (60 Ci/mmol) were from Dupont NEN. The p42/p44
mitogen-activated protein (MAP) kinase kit was bought from New
England Biolabs; the p70 S6 kinase (p70 S6K), phosphatidylinositol
3P-kinase (PI3K), Akt/PKB and c-Raf-1 assay kits were from Upstate
Biotechnology. p-TYR (PY20)^agarose conjugate was from Santa
Cruz Biotechnology. Tissue culture reagents, including Dulbecco’s
modi¢ed Eagle’s medium (DMEM) and fetal calf serum were bought
from Gibco-BRL.
2.2. Cell culture
The NIH 3T3 clone-7 and H-ras-transformed NIH 3T3 ¢broblast
lines were provided by Dr. Douglas R. Louis (National Cancer In-
stitute, National Institutes of Health, Bethesda, MD, USA) and main-
tained in DMEM as described previously [22]. The HTB-157 fetus
(second trimester) lung ¢broblast-like cells, bought from the American
Type Culture Collection, were cultured in 10% fetal calf serum-con-
taining DMEM as indicated in [22].
2.3. Assay of ALP activity
ALP activity was assayed spectrophotometrically by monitoring the
hydrolysis of 4-nitrophenylphosphate (as an increase in absorbance at
410 nm) at room temperature (22‡C) under conditions as described in
[23]. The extinction coe⁄cient of 4-nitrophenol was taken as
1.62U104 M31 cm31. One unit enzyme activity is de¢ned as 1 Wmol
substrate hydrolyzed/min at 22‡C at pH 9.8.
2.4. Puri¢cation of human PALP
A partially puri¢ed human PALP preparation from Sigma was ¢rst
further puri¢ed by successive concanavalin A-Sepharose and Q-
Sepharose chromatography as described by Chang et al. [24]. Finally,
the Q-Sepharose PALP fraction (which still contained two major pro-
teins) was puri¢ed to homogeneity by t-butyl HIC chromatography
[24]. The 5 ml bed volume t-butyl HIC cartridge was connected to a
Pharmacia FPLC system. The PALP activity was assayed as above.
Purity of the enzyme was con¢rmed by SDS^PAGE using Coomassie
blue stain.
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2.5. Determination of DNA synthesis
Fibroblasts were grown in 12-well tissue culture dishes to about 40^
50% con£uency in 10% fetal calf serum-containing DMEM, washed
and then incubated in serum-free medium for 27 h. The cells were
washed and then treated for 17 h in serum-free medium with PALP or
other ALPs in the absence or presence of insulin and/or calcium/zinc,
followed by incubation for 1 h in the presence of [3H]thymidine (1
WCi/well). In these experiments, PALP was added to the cells 10 and
20 min prior to calcium/zinc and insulin, respectively; however, PALP
was equally e¡ective when added 20 min prior to or 10 min after
insulin. The cells were washed twice with PBS, then four times with
5% trichloroacetic acid and, ¢nally, twice with absolute ethanol. The
acid-insoluble material was redissolved in 0.3 M sodium hydroxide
and then 3H activity was counted.
2.6. MAP kinase phosphorylation assay
Serum-starved NIH 3T3 ¢broblasts, grown in 35-mm diameter
dishes to 70^80% con£uency, were incubated for 10 min with 200
nM PALP, TNSALP (1 U/ml) or IALP (1 U/ml) in the absence or
presence of 500 nM insulin plus 2.8 mM calcium. Samples for West-
ern immunoblot analysis were prepared as described earlier [25]. A
phospho-speci¢c antibody (New England Biolabs), recognizing specif-
ic, activating, phosphorylated sites in p42/p44 MAP kinases was used
to quantitate the phosphorylated/activated forms of these enzymes.
The relative changes in the intensity of phosphorylation were deter-
mined by a Storm 840 phosphorImager (Molecular Dynamics).
2.7. In vitro kinase assays
Serum-starved (24 h) NIH 3T3 cells, grown in six-well plates, were
¢rst treated with 200 nM PALP for 2 min then with 500 nM insulin
for 5 min. Enzyme assays were performed for 10 min; each enzyme
reaction was linear during this time period.
To determine p70 S6K activity, immunoprecipitates, prepared from
cell extracts by using anti-rabbit polyclonal p70 S6 kinase antibody,
were used to phosphorylate the substrate peptide AKRRRLSSLRA
[26]. p70 S6 kinase activity is expressed as the amount of 32P (dpm)
transferred from [Q-32P]ATP to the substrate peptide per 1 mg (pre-
immunocomplex) protein during 1 min incubation at 30‡C.
PI3K activity was determined as described earlier [27]. Brie£y, PI3K
was immunoprecipitated from cell extracts with PY20^agarose conju-
gate and then incubated with the substrates phosphatidylinositol and
[Q-32P]ATP, followed by the separation of the product
[32P]phosphatidylinositol 3-phosphate. The product was visualized
and quantitatively analyzed by the Storm phosphorImager. PI3K ac-
tivity is expressed as the amount of 32P (dpm) incorporated into phos-
phatidylinositol 3-phosphate per 1 mg (pre-immunocomplex) protein
during 1 min incubation at 30‡C.
The activity of Akt/PKB was determined in immunoprecipitates by
using [Q-32P]ATP and the RPRAATF peptide as substrates, as de-
scribed previously [26]. The enzyme activity is expressed as the
amount of 32P (dpm) incorporated into the substrate peptide per
1 mg (pre-immunocomplex) protein during 1 min incubation at 30‡C.
c-Raf-1 kinase was immunoprecipitated from 0.5 ml cell lysate (250
Wg protein) with 2 Wg of anti-human c-Raf-1 antibody (Upstate Bio-
technology) plus 50 Wl of protein A/G agarose (Santa Cruz Biotech-
nology). c-Raf-1 activity was determined by an in vitro kinase cascade
reaction according to the manufacturer’s (Upstate Biotechnology) in-
structions. Brie£y, the immunocomplex ¢rst catalyzes phosphory-
lation and activation of inactive MAP kinase kinase, followed by
the phosphorylation (by MAP kinase kinase) and activation of p42/
p44 MAP kinases. MAP kinase activity is then determined by the
phosphorylation of myelin basic protein in the presence of [Q-32P]ATP.
c-Raf-1 activity is expressed as the amount of 32P (dpm) incorporated
into myelin basic protein per 1 mg (pre-immunocomplex) protein
during 1 min incubation at 30‡C.
2.8. Cell proliferation assay
Changes in the number of viable cells in serum-starved (24 h) NIH
3T3 cultures (cells seeded in 96-well plates at 1000 cells per well) upon
treatments with PALP and insulin were determined by the MTT
method [28] as described previously in detail [29]. A Labsystem Mul-
tiskan MS microplate reader was used to read absorbance and to
analyze data [29].
3. Results
Sigma PALP was used as the starting material to obtain a
completely puri¢ed enzyme fraction which, after separation by
gel electrophoresis, contained only one band (Fig. 1). Eight
di¡erent preparations of PALP, consistently expressing 12^15-
times higher speci¢c activity (on average, 120 U/mg protein)
than the Sigma preparation, were used during this study with
no detectable di¡erences in their e¡ects on mitogenesis and
signal transduction. PALP is known to be a highly thermo-
stable enzyme; accordingly, heating the enzyme at 65‡C for 30
min did not change enzyme activity. In most experiments we
used both untreated PALP (uPALP) and preheated PALP
(hPALP).
Fig. 1. Final puri¢cation of Sigma-produced PALP. Partially puri-
¢ed Sigma PALP preparation (lane 2; SDS^PAGE, Coomassie blue
stain) was further puri¢ed by successive concanavalin A-Sepharose
(lane 3), Q-Sepharose (lane 4) and t-butyl HIC chromatography (2^
0 M ammonium sulfate gradient) (lane 5). Lane 1 shows the molec-
ular mass standards. Each (eight) preparation of puri¢ed PALP
used in this study showed a single band.
Table 1
Stimulatory e¡ects of PALP and insulin on signal transducing enzymes
Addition Enzyme activity (32P-labeling (dpm)/mg protein/min)
p70 S6K PI3K Akt kinase Raf-1 kinase
None 3 410; 2 850 14 820; 10 760 1 830; 1 810 850; 520
hPALP, 40 nM 11 290; 10 710 40 000; 31 620 2 110; 2 070 2 970; 2 080
hPALP, 100 nM 15 200; 14 980 45 820; 36 800 3 580; 3 330 3 560; 3 250
hPALP, 200 nM 22 050; 20 510 52 230; 52 130 8 240; 7 680 4 850; 4 740
uPALP, 200 nM 20 100; 10 010 46 330; 46 270 5 180; 4 690 3 650; 3 440
Insulin 26 360; 23 790 300 000; 256 100 126 890; 118 060 1 130; 950
hPALP, 200 nM+insulin 28 410; 26 990 288 660; 232 050 121 350; 116 670 9 850; 9 055
Serum-starved (24 h) NIH 3T3 ¢broblasts were ¢rst treated with various concentrations of hPALP or uPALP, as indicated, for 2 min and then
with 500 nM insulin for 5 min. This was followed by the enzyme assays as described in Section 2. Data for each enzyme activity, expressed as
32P-labeling of the speci¢c substrate by 1 mg of (preimmunocomplex) protein per 1 min, are given for each of the two experiments performed.
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In serum-starved mouse NIH 3T3 ¢broblasts, 40^200 nM
concentrations of uPALP alone stimulated DNA synthesis
2.6^4.1-fold and, importantly, they also potentiated the stim-
ulatory e¡ect of insulin (Fig. 2A). Unexpectedly, hPALP had
greater e¡ects than uPALP on DNA synthesis (Fig. 2A). Of
potential interest is that preheated PALP retained its greater
mitogenic activity for at least three days at 4‡C. Pretreatments
at 75‡C similarly increased the mitogenic activity of PALP,
while pretreatments at 55 and 85‡C caused 40 and 55% less
activation of PALP, respectively. A PALP speci¢c antibody
(Zymed; 50 Wg/ml) inhibited the stimulatory e¡ects of 200 nM
(V25 Wg/ml) hPALP and uPALP on DNA synthesis about
80^85%, but it did not modify the e¡ects of 10% serum, 500
nM insulin or 20 ng/ml ¢broblast growth factor. This further
con¢rmed that PALP, and not an invisible minor contami-
nant, was the source of mitogenic activity. We should add
here that neither TNSALP nor IALP, used at 0.1^5 U/ml
concentrations, stimulated DNA synthesis in the absence or
presence of insulin (data not shown). These ¢ndings, com-
bined with the observed increase in the mitogenic but not
catalytic activity of PALP upon heating (Fig. 2A), suggest
that PALP acts on DNA synthesis by a mechanism which
may not require its phosphatase activity.
The DMEM medium used for cell culture contains 1.8 mM
calcium (Ca2). As shown in Fig. 2B, maximal synergistic
e¡ects of uPALP and insulin occurred at this Ca2 concen-
tration, but well detectable e¡ects also were observed at 0.8^
1.3 mM Ca2 concentrations. At 2.3^2.8 mM concentrations,
Ca2 itself greatly enhanced the e¡ect of insulin and PALP
had only little or no additional e¡ects (Fig. 2B). As reported
earlier [30], 3.8 mM Ca2 maximally enhanced the mitogenic
e¡ect of insulin; again, under this latter condition PALP had
no additional e¡ect (data not shown).
The mitogenic activity of uPALP was also potentiated by
25 WM zinc chloride (Fig. 2C). We should note here that
PALP is a zinc enzyme and during the various steps of the
puri¢cation procedure the enzyme could lose some zinc.
Therefore, it is possible that the potentiating e¡ect of zinc
Fig. 2. PALP stimulates DNA synthesis in various cell lines. (A) Se-
rum-starved NIH 3T3 ¢broblasts were treated for 18 h with 0^400
nM uPALP or hPALP in the absence or presence of 500 nM insu-
lin, as indicated. (B) Serum-starved NIH 3T3 ¢broblasts were
treated for 18 h with 200 nM uPALP þ 500 nM insulin in the pres-
ence of 0.3^2.8 mM Ca2 in the medium, as indicated. (C) Serum-
starved NIH 3T3 ¢broblasts were treated for 18 h with 200 nM uP-
ALP þ 25 WM ZnCl2 in the presence of 0.8^3.3 mM Ca2, as indi-
cated. (D) Serum-starved fetal lung ¢broblasts (open symbols) and
H-ras-transformed NIH 3T3 ¢broblasts (closed symbols) were
treated for 18 h with 200 nM uPALP þ 500 nM insulin, as indi-
cated. In each case, error bars indicate S.D. (n = 6). Each experi-
ment presented was repeated at least twice with essentially equiva-
lent results.
Fig. 3. Stimulatory e¡ects of PALP and insulin on the proliferation
of NIH 3T3 ¢broblasts. Serum-starved (24 h) cells were incubated
for up to 7 days in the absence (b) or presence of 200 nM uPALP
(R), 500 nM insulin (Ins) (F) or 200 nM uPALP plus 500 nM insu-
lin (8), followed by the determination of viable cells by the MTT
assay as described in Section 2. Each point represents the mean þ
S.E.M. of three separate experiments (n = 16).
Fig. 4. E¡ects of ALPs, Ca2 and insulin on p42/p44 MAP kinase
phosphorylation. Serum-starved NIH 3T3 cells were treated with
puri¢ed (non heat-treated) PALP (200 nM) as well as Sigma
TNSALP or IALP, each at 1 U/ml concentration, for 2 min, fol-
lowed by treatments for 10 min with 500 nM insulin and/or 1 mM
extra Ca2 (2.8 mM total Ca2) as shown. The stimulatory e¡ects
of PALP in the absence as well as presence of insulin plus Ca2
were con¢rmed in three additional experiments.
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merely re£ects that the mitogenic e¡ect of PALP requires
enzyme bound zinc (which is absent from DMEM). Alterna-
tively, since zinc sensitizes these ¢broblasts to the mitogenic
actions of Ca2 [30], zinc could also act by lowering the con-
centration of Ca2 required for the action of PALP. Further
work is required to resolve this issue.
In serum-starved lung ¢broblasts originally derived from a
4-month-old fetus, 200 nM uPALP stimulated DNA synthesis
5-fold and it also enhanced the insulin e¡ect 2.3-fold (Fig.
2D). Similarly, in serum-starved Ha-Ras-transformed NIH
3T3 ¢broblasts, 200 nM uPALP had 1.5^1.7-fold stimulatory
e¡ects on DNA synthesis both in the absence and presence of
insulin (Fig. 2D).
Serum starvation usually elicits rapid apoptotic cell death in
most ¢broblast lines. However, incubation of NIH 3T3 ¢bro-
blasts in serum-free medium for 2 days did not reduce the
number of viable cells as determined by the MTT colorimetric
assay (Fig. 3) and veri¢ed by direct cell counting. During the
¢rst 2 days of incubation, exposure to insulin and PALP en-
hanced cell numbers 1.38- and 1.75-fold, respectively, while in
combination they had about a two-fold e¡ect (Fig. 3). After
incubations for 5 or 7 days, the number of cells both in the
untreated and treated cultures were substantially reduced with
similar kinetics (Fig. 3). These data indicated that while both
PALP and insulin, particularly in combination, increase cell
proliferation, in this cellular system none of them can prevent
serum de¢ciency-induced cell death.
In serum-starved NIH 3T3 and fetal ¢broblasts, the e¡ects
of hPALP as well as hPALP plus insulin on DNA synthesis
were inhibited 51^58% by 50 WM PD 98059, a MAP kinase
kinase inhibitor [31], 72^83% by rapamycin (10 WM), a speci¢c
inhibitor of the actions of p70 S6K [32], and 20^27% by
wortmannin (200 nM), an inhibitor of PI3K [33]. These
data suggested that PALP may stimulate both the c-Raf-1
kinaseCMAP kinase and the p70 S6K-dependent mitogenic
pathways.
PI3K and Akt/PKB often mediate the p70 S6K-activating
e¡ects of insulin and other growth factors [34^36]. In serum-
starved NIH 3T3 ¢broblasts, both hPALP and uPALP in-
creased the activities of PI3K, Akt/PKB, p70 S6K and c-
Raf-1 kinase (Table 1). However, insulin was more e¡ective
than hPALP in stimulating p70 S6K, and particularly PI3K
and Akt/PKB activities, and none of these insulin e¡ects were
enhanced by hPALP (Table 1). Unexpectedly, insulin alone
failed to activate c-Raf-1 kinase activity, yet it enhanced the
stimulatory e¡ect of hPALP (Table 1).
Activating phosphorylation of p42/p44 MAP kinases is re-
quired for mitogenesis in ¢broblasts [37]. At 200-nM concen-
tration, uPALP enhanced activating phosphorylation of p42/
p44 MAP kinases 8^11-fold as determined by a phosphorIm-
ager (Fig. 4). In addition, PALP also approximately doubled
the large (17^24-fold) stimulatory e¡ects of insulin plus 2.8
mM Ca2 (Fig. 4). These stimulatory e¡ects of PALP were
highly reproducible in four experiments. In contrast to PALP,
neither TNSALP nor IALP a¡ected MAP kinase phosphory-
lation (Fig. 4). Finally, hPALP (200 nM) was only slightly
more e¡ective than uPALP (200 nM) in stimulating MAP
kinase phosphorylation (not shown).
In conclusion, we have found that in untransformed and H-
ras-transformed mouse NIH 3T3 ¢broblasts as well as fetal
¢broblasts, PALP, particularly in combination with insulin,
increases mitogenesis in a Ca2-dependent manner. Heat
treatment and zinc increase the mitogenic activity of PALP
by presently unknown mechanisms. Importantly, the mitogen-
ic activity of PALP may be independent of its phosphatase
activity. The e¡ects of PALP on DNA synthesis are associated
with the activation of p42/p44 MAP kinases, p70 S6K, PI3K,
Akt/PKB kinase and c-Raf-1 kinase. The signi¢cance of these
enzymes in the mediation of PALP e¡ects on DNA synthesis
remains to be determined. These results suggest that PALP
may be a positive regulator of fetus growth and, when ex-
pressed, it may also increase the growth of tumor cells which
express oncogenic Ras.
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